PE20211299A1 - Receptores de antigeno quimericos dirigidos a cd70 - Google Patents
Receptores de antigeno quimericos dirigidos a cd70Info
- Publication number
- PE20211299A1 PE20211299A1 PE2020001165A PE2020001165A PE20211299A1 PE 20211299 A1 PE20211299 A1 PE 20211299A1 PE 2020001165 A PE2020001165 A PE 2020001165A PE 2020001165 A PE2020001165 A PE 2020001165A PE 20211299 A1 PE20211299 A1 PE 20211299A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen receptors
- cars
- immune cell
- relates
- car
- Prior art date
Links
- 102100025221 CD70 antigen Human genes 0.000 title abstract 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 title abstract 4
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 3
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 108020001756 ligand binding domains Proteins 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invencion se refiere a receptores de antigenos quimericos (CAR) que se unen especificamente a CD70, el cual comprende: un dominio de union a ligando extracelular conformado por scFv de union a CD70, un primer dominio transmembrana y un dominio de senalizacion intracelular. La invencion tambien se refiere a polinucleotidos que codifican CAR, un vector de expresion, una celula inmunitaria modificada por ingenieria genetica que expresa dicho CAR, un metodo para modificar por ingenieria genetica una celula inmunitaria y una composicion farmaceutica. Dichos CAR son utiles para el tratamiento de una afeccion asociada con celulas malignas que expresan CD70, por ejemplo, en el cancer
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625019P | 2018-02-01 | 2018-02-01 | |
US201862625009P | 2018-02-01 | 2018-02-01 | |
US201862641873P | 2018-03-12 | 2018-03-12 | |
US201862641869P | 2018-03-12 | 2018-03-12 | |
US201862775246P | 2018-12-04 | 2018-12-04 | |
PCT/US2019/016189 WO2019152742A1 (en) | 2018-02-01 | 2019-01-31 | Chimeric antigen receptors targeting cd70 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211299A1 true PE20211299A1 (es) | 2021-07-20 |
Family
ID=65686921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001165A PE20211299A1 (es) | 2018-02-01 | 2019-01-31 | Receptores de antigeno quimericos dirigidos a cd70 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11396551B2 (es) |
EP (1) | EP3746483A1 (es) |
JP (2) | JP7404247B2 (es) |
KR (1) | KR20200128018A (es) |
CN (1) | CN112020518A (es) |
AU (1) | AU2019216420A1 (es) |
BR (1) | BR112020015662A2 (es) |
CA (1) | CA3089318A1 (es) |
IL (1) | IL276396A (es) |
MX (1) | MX2020008184A (es) |
PE (1) | PE20211299A1 (es) |
PH (1) | PH12020551160A1 (es) |
SG (1) | SG11202006883QA (es) |
TW (1) | TW201936633A (es) |
WO (1) | WO2019152742A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
JP2021511811A (ja) | 2018-02-01 | 2021-05-13 | ファイザー・インク | Cd70に特異的な抗体およびその使用 |
MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
US20210079347A1 (en) * | 2019-09-06 | 2021-03-18 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
EP4031150A4 (en) * | 2019-09-16 | 2023-11-01 | The General Hospital Corporation | CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF |
JP2023501590A (ja) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Cd70を標的化する遺伝子操作されたt細胞を使用する造血細胞悪性腫瘍のための療法 |
BR112022009137A2 (pt) * | 2019-11-13 | 2022-07-26 | Crispr Therapeutics Ag | Métodos de fabricação de células t com receptor de antígeno quimérico (car) |
JP2023501602A (ja) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Cd70を標的化する遺伝子操作されたt細胞を使用する腎細胞癌(rcc)療法 |
CA3158114A1 (en) * | 2019-11-13 | 2021-05-20 | Jonathan Alexander Terrett | Cd70+ solid tumor therapy using genetically engineered t cells targeting cd70 |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
WO2021226289A2 (en) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins |
WO2022076788A1 (en) * | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
US20230051406A1 (en) | 2020-11-13 | 2023-02-16 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
AU2021409801A1 (en) | 2020-12-21 | 2023-06-22 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
AU2022212130A1 (en) | 2021-01-29 | 2023-07-06 | Allogene Therapeutics, Inc. | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS |
TW202309077A (zh) * | 2021-05-12 | 2023-03-01 | 瑞士商Crispr治療公司 | 用於治療實性瘤的靶向cd70的基因工程化免疫細胞 |
WO2022238962A1 (en) * | 2021-05-12 | 2022-11-17 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
EP4355358A1 (en) * | 2021-06-15 | 2024-04-24 | Allogene Therapeutics, Inc. | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
CN117897405A (zh) * | 2021-06-30 | 2024-04-16 | 得克萨斯大学体系董事会 | 靶向cd70-阳性癌症的多肽 |
WO2023072307A1 (zh) * | 2021-10-25 | 2023-05-04 | 重庆精准生物技术有限公司 | 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用 |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ATE277193T1 (de) | 1989-03-21 | 2004-10-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
CA2166118C (en) | 1993-06-24 | 2007-04-17 | Frank L. Graham | Adenovirus vectors for gene therapy |
EP0814154B1 (en) | 1993-09-15 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus vectors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
EP0772689B1 (en) | 1994-05-09 | 2007-12-19 | Oxford Biomedica (UK) Limited | Retroviral vectors having a reduced recombination rate |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
CA2511598C (en) | 2002-12-24 | 2016-09-13 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
EP1799262A4 (en) | 2004-10-15 | 2009-10-21 | Seattle Genetics Inc | ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS |
CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
DK1871418T3 (da) | 2005-04-19 | 2014-06-10 | Seattle Genetics Inc | Humaniserede anti-cd70-bindende midler og anvendelser deraf |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
EP2335744A4 (en) | 2008-08-26 | 2011-07-27 | Univ Hokkaido Nat Univ Corp | BONE-FILLING AGENT FOR INTRODUCING CARTILAGE REGENERATION |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
WO2012058458A2 (en) | 2010-10-27 | 2012-05-03 | Cellectis Sa | Method for increasing the efficiency of double-strand break-induced mutagenesis |
EP2632482A4 (en) * | 2010-10-27 | 2015-05-27 | Baylor College Medicine | CHIMERIC CD27 RECEPTORS FOR REALIGNMENT OF T CELLS TO CD70 POSITIVE MALIGNOMES |
CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
BR112013021562B1 (pt) | 2011-03-16 | 2023-01-10 | Argenx Bvba | Anticorpos para cd70 |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
JP6352920B2 (ja) | 2012-09-04 | 2018-07-04 | セレクティス | 多重鎖キメラ抗原受容体およびその使用 |
RU2725542C2 (ru) | 2013-05-13 | 2020-07-02 | Селлектис | Способы конструирования высокоактивных т-клеток для иммунотерапии |
CN109897100A (zh) | 2013-05-13 | 2019-06-18 | 瑟勒提斯公司 | Cd19特异性嵌合抗原受体及其用途 |
DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
EP3027224B1 (en) | 2013-07-31 | 2020-06-03 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
MX2016010345A (es) | 2014-02-14 | 2017-01-23 | Cellectis | Celulas para inmunoterapia diseñadas para dirigir antigeno presente tanto en celulas inmunes y celulas patologicas. |
EP3230310B1 (en) * | 2014-12-08 | 2019-06-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd70 chimeric antigen receptors |
ES2842212T3 (es) * | 2015-01-26 | 2021-07-13 | Cellectis | Receptores de antígenos quiméricos monocatenarios específicos anti-CLL1 (scCAR) para inmunoterapia contra el cáncer |
DE102015101304B3 (de) | 2015-01-29 | 2016-03-17 | Fujitsu Technology Solutions Intellectual Property Gmbh | Rackserver für ein Serverrack |
BR112017019785B1 (pt) | 2015-04-13 | 2022-11-16 | Pfizer Inc | Anticorpo biespecífico, seu uso e composição farmacêutica |
EP3757128A1 (en) * | 2015-04-13 | 2020-12-30 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TW201936640A (zh) | 2016-01-21 | 2019-09-16 | 美商輝瑞股份有限公司 | 對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
TWI785009B (zh) * | 2017-02-14 | 2022-12-01 | 美商凱特製藥公司 | Cd70結合分子及使用彼之方法 |
JP2021511811A (ja) | 2018-02-01 | 2021-05-13 | ファイザー・インク | Cd70に特異的な抗体およびその使用 |
-
2019
- 2019-01-31 WO PCT/US2019/016189 patent/WO2019152742A1/en unknown
- 2019-01-31 CA CA3089318A patent/CA3089318A1/en active Pending
- 2019-01-31 KR KR1020207025214A patent/KR20200128018A/ko not_active Application Discontinuation
- 2019-01-31 AU AU2019216420A patent/AU2019216420A1/en active Pending
- 2019-01-31 CN CN201980024740.XA patent/CN112020518A/zh active Pending
- 2019-01-31 BR BR112020015662-0A patent/BR112020015662A2/pt unknown
- 2019-01-31 EP EP19709580.5A patent/EP3746483A1/en active Pending
- 2019-01-31 TW TW108103959A patent/TW201936633A/zh unknown
- 2019-01-31 PE PE2020001165A patent/PE20211299A1/es unknown
- 2019-01-31 MX MX2020008184A patent/MX2020008184A/es unknown
- 2019-01-31 US US16/264,371 patent/US11396551B2/en active Active
- 2019-01-31 SG SG11202006883QA patent/SG11202006883QA/en unknown
- 2019-01-31 JP JP2020541882A patent/JP7404247B2/ja active Active
-
2020
- 2020-07-29 IL IL276396A patent/IL276396A/en unknown
- 2020-07-30 PH PH12020551160A patent/PH12020551160A1/en unknown
-
2022
- 2022-06-17 US US17/843,616 patent/US20230041456A1/en active Pending
-
2023
- 2023-10-12 JP JP2023176445A patent/JP2024016034A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3089318A1 (en) | 2019-08-08 |
AU2019216420A1 (en) | 2020-08-20 |
TW201936633A (zh) | 2019-09-16 |
JP7404247B2 (ja) | 2023-12-25 |
KR20200128018A (ko) | 2020-11-11 |
JP2021511807A (ja) | 2021-05-13 |
JP2024016034A (ja) | 2024-02-06 |
WO2019152742A1 (en) | 2019-08-08 |
MX2020008184A (es) | 2020-09-22 |
BR112020015662A2 (pt) | 2020-12-08 |
EP3746483A1 (en) | 2020-12-09 |
SG11202006883QA (en) | 2020-08-28 |
RU2020128741A (ru) | 2022-03-01 |
CN112020518A (zh) | 2020-12-01 |
US11396551B2 (en) | 2022-07-26 |
US20190233528A1 (en) | 2019-08-01 |
PH12020551160A1 (en) | 2021-05-31 |
IL276396A (en) | 2020-09-30 |
US20230041456A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211299A1 (es) | Receptores de antigeno quimericos dirigidos a cd70 | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
PE20181066A1 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
CO2021010075A2 (es) | Receptores de antígenos quiméricos de gprc5d y células que los expresan | |
MX2019001184A (es) | Anticuerpos anti-idiotípicos y métodos relacionados. | |
MD3652215T2 (ro) | Moleculă polipeptidică îmbunătăţită cu specificitate duală | |
CO2019011155A2 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
MX2020013443A (es) | Receptores de antigeno quimerico de bcma y usos de los mismos. | |
CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
PE20191717A1 (es) | Dominio de union antigeno anti-trbc1 | |
UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
CO2017006808A2 (es) | Receptores de antígenos quiméricos de bcma | |
PE20200400A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
CO2019013654A2 (es) | Receptores de antígenos quiméricos que se dirigen a flt3 | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
CL2016000376A1 (es) | Anticuerpos anti-prlr y sus usos | |
UY37105A (es) | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t | |
BR112018067698A2 (pt) | células modificadas para imunoterapia | |
PE20171383A1 (es) | Receptores de antigeno quimericos anti-dll3 y metodos de uso | |
CU24475B1 (es) | Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 | |
PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
GT201300150A (es) | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer | |
CL2021002500A1 (es) | Anticuerpos anti-egfrviii y fragmentos de unión a antígeno de los mismos | |
MX2020012445A (es) | Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos. |